DGAP-News: Apricus Biosciences and Stellar Pharmaceuticals Announce Exclusive License Agreement in Canada for the Commercialization of MycoVa(TM) for Onychomycosis
Apricus Biosciences, Inc.
03.01.2012 15:00
—————————————————————————
Apricus Bio Can Receive Up to Approximately $8 Million (Canadian) Plus Tiered
Double Digit Royalties Under Multi-year Agreement
Stellar Pharma Strengthens Its Dermatology Business in Canada With Its Second
Prescription Product, MycoVa(tm)
SAN DIEGO and MILTON, Ontario, Jan. 3, 2012 (GLOBE
